

GenCore version 5.1.4_p5_4578
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: March 10, 2003, 21:31:17 ; Search time 156.822 Seconds
(without alignments)
488.248 Million cell updates/sec

Title: US-09-913-524-33

Perfct score: 34

Sequence: 1 aggcctcgaggagcaacgctgcccactgccaact 34

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 1125999159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : N_Geneseq_101002.*
1: /SID32/gcgdata/geneseq/geneseq-emb1/NA1980.DAT.*
2: /SID32/gcgdata/geneseq/geneseq-emb1/NA1981.DAT.*
3: /SID32/gcgdata/geneseq/geneseq-emb1/NA1982.DAT.*
4: /SID32/gcgdata/geneseq/geneseq-emb1/NA1983.DAT.*
5: /SID32/gcgdata/geneseq/geneseq-emb1/NA1984.DAT.*
6: /SID32/gcgdata/geneseq/geneseq-emb1/NA1985.DAT.*
7: /SID32/gcgdata/geneseq/geneseq-emb1/NA1986.DAT.*
8: /SID32/gcgdata/geneseq/geneseq-emb1/NA1987.DAT.*
9: /SID32/gcgdata/geneseq/geneseq-emb1/NA1988.DAT.*
10: /SID32/gcgdata/geneseq/geneseq-emb1/NA1989.DAT.*
11: /SID32/gcgdata/geneseq/geneseq-emb1/NA1990.DAT.*
12: /SID32/gcgdata/geneseq/geneseq-emb1/NA1991.DAT.*
13: /SID32/gcgdata/geneseq/geneseq-emb1/NA1992.DAT.*
14: /SID32/gcgdata/geneseq/geneseq-emb1/NA1993.DAT.*
15: /SID32/gcgdata/geneseq/geneseq-emb1/NA1994.DAT.*
16: /SID32/gcgdata/geneseq/geneseq-emb1/NA1995.DAT.*
17: /SID32/gcgdata/geneseq/geneseq-emb1/NA1996.DAT.*
18: /SID32/gcgdata/geneseq/geneseq-emb1/NA1997.DAT.*
19: /SID32/gcgdata/geneseq/geneseq-emb1/NA1998.DAT.*
20: /SID32/gcgdata/geneseq/geneseq-emb1/NA1999.DAT.*
21: /SID32/gcgdata/geneseq/geneseq-emb1/NA2000.DAT.*
22: /SID32/gcgdata/geneseq/geneseq-emb1/NA2001A.DAT.*
23: /SID32/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT.*
24: /SID32/gcgdata/geneseq/geneseq-emb1/NA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	33	97.1	405	22	AAF84904 Nucleotide sequence
2	33	97.1	1134	7	AA60428 Sequence encoding
3	33	97.1	1237	8	AA70314 Sequence encoding
4	33	97.1	1338	9	AA80040 Sequence encoding
5	33	97.1	3422	22	AA03358 Human reproductive
6	33	97.1	3422	22	AA03360 Human reproductive
7	33	97.1	3422	22	AA28909 Human immunoglobul
8	33	97.1	3422	22	AA28911 Human immunoglobul
9	25	73.5	1182	7	AA60426 Sequence encoding

10	23.4	68.8	1343	8	AA70310 Sequence encoding
11	20.8	61.2	5145	22	AA06014 Human neuronal apo
12	19.8	58.2	5172	23	ABL12657 Drosophila melanog
13	19.8	58.2	6410	23	ABL12656 Drosophila melanog
14	19.6	57.6	1500	17	AA06947 C-promoter binding
15	19.6	57.6	1580	20	AA39671 Renal cancer assoc
16	19.6	57.6	1580	22	AA01117 Human small cell l
17	19.4	57.1	1087	22	AA14269 Human cDNA sequenc
18	19.4	57.1	1125	21	AA16239 Human prostate can
19	19.4	57.1	1183	21	AA298235 Human signal pepti
20	19.4	57.1	1279	23	ABL04895 Drosophila melanog
21	19.4	57.1	2297	22	AA098586 Human EST-derived
22	19.4	57.1	3210	23	ABL12861 Drosophila melanog
23	19.4	57.1	3333	23	ABL04894 Drosophila melanog
24	19.4	57.1	4219	23	ABL04902 Drosophila melanog
25	19.4	57.1	5981	23	ABL12860 Drosophila melanog
26	19.4	57.1	6109	23	AA078667 Murine Col5a3 cDNA
27	19.2	56.5	1812	22	AA08562 Human partial card
28	19.2	56.5	2127	19	AA023246 Human adenylylcycl
29	19.2	56.5	3192	22	AA521281 Human cDNA sequenc
30	19.2	56.5	3549	22	AA08563 Human cardiac aden
31	19.2	56.5	3552	22	AA08567 Human cardiac aden
32	19.2	56.5	4046	14	AA042525 Cardiac adenylyl c
33	19.2	56.5	4131	21	AA53923 Type VI adenylyl c
34	19.2	56.5	4942	20	AA00461 Human type VI aden
35	19.2	56.5	32082	22	AA06991 Human reproductive
36	19.2	56.5	45546	20	AA23520 Human kidney amino
37	19.2	55.9	613	19	AAV15304 Breast cancer-asso
38	19.2	55.9	613	22	AA025901 Human breast cance
39	19.2	55.9	903	22	AA081747 Human differential
40	19.2	55.9	903	22	AA025902 Human breast cance
41	19.2	55.9	1123	22	AA189533 Human polynucleoti
42	19.2	55.9	3205	23	ABL15045 Drosophila melanog
43	19.2	55.9	4063	22	AA070341 Human immune/haema
44	19.2	55.9	4063	22	AA082280 Human immune/haema
45	19.2	55.9	4935	23	ABL15050 Drosophila melanog

ALIGNMENTS

RESULT 1

AAF84904 standard; DNA; 405 BP.

ID AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

XX AAF84904

PI Groome NP, Milne-Robertson DM, Stanton PG, Cahir NF;
 XX WPI: 2001-308476/32.
 DR P-PSDB; AAB68139.
 XX
 PT Immuno-interactive fragments of alpha-C portion of mammalian inhibin
 PT alpha-subunit used to, e.g. produce antigen-binding molecules for
 PT diagnosing cancer.
 XX
 PS Example 2; Page 138-139; 159pp; English.
 XX
 CC The present sequence encodes an alphaC portion of a human inhibin
 CC alpha-subunit. Inhibin is a dimeric glycoprotein which is able to
 CC inhibit the secretion of follicle stimulating hormone (FSH) by the
 CC pituitary. Immuno-interactive fragments of the alphaC portion of inhibin
 CC alpha-subunit are used to raise antibodies. The antibodies are used to
 CC diagnose cancer of tissues in the ovary, uterus, breast, pituitary,
 CC testis, or prostate. The antibodies may be used in immunoassays such
 CC as radio-immunoassays, affinity chromatography in isolating a natural
 CC or recombinant mammalian inhibin, and for screening expression
 CC libraries for variant polypeptides.
 XX
 SQ Sequence 405 BP; 68 A; 148 C; 96 G; 93 T; 0 other;
 Query Match 97.1%; Score 33; DB 22; Length 405;
 Best Local Similarity 97.1%; Pred. No. 0.00059;
 Matches 33; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 AGGCCTCCGGAGGACCGNCTGCCCATGCCCAACT 34
 DB 55 AGGCCTCCGGAGGACCGGCTGCCCATGCCCAACT 88
 RESULT 2
 AAN60428
 ID AAN60428 standard; cDNA; 1134 BP.
 AC
 AC AAN60428;
 XX
 DT 26-JUN-1991 (first entry)
 XX
 DE Sequence encoding human inhibin A subunit.
 XX
 KW Hormone; inhibin agonist; antagonist; reproductive; gonad; ss.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT CDS 8..190
 FT /*tag= a
 FT mat_peptide 191..1108
 FT /*tag= b
 XX
 PN W08605076-A.
 XX
 PD 23-OCT-1986.
 XX
 PY 14-APR-1986; 86WO-AU00097.
 XX
 PR 20-DEC-1985; 85AU-0003961.
 PR 18-APR-1985; 85AU-0000194.
 PR 06-SEP-1985; 85AU-0002320.
 PR 29-OCT-1985; 85AU-0003157.
 PR 19-DEC-1985; 85AU-0003960.
 PR 01-JAN-1986; 86AU-0059039.
 PR 02-APR-1987; 87AU-0071015.
 PR 05-MAY-1986; 86CN-0103459.
 XX
 PA (BIOT-) BIOTECHN AUSTR PTY.
 PA (MONU) MONASH UNIV.
 PA (HENR-) PRICE HENRY'S HOSPITAL.
 PA (SVIN-) ST VINCENTS'S INST MED RE.
 XX

PI Forage R, Stewart A, Robertson D, Dekretser DM;
 XX WPI: 1986-291647/44.
 DR P-PSDB; AAP60519.
 XX
 PT New polynucleotide sequences and recombinant DNA - encoding
 PT inhibin and synthetic peptides useful for affecting gonadal
 PT function
 XX
 PS Claim 8; Fig 7; 71pp; English.
 XX
 CC DNA encoding inhibin and inhibin or part, analogues, homologues or
 CC precursors thereof when produced by recombinant techniques are also
 CC claimed, as well as pharmaceutical compositions thereof. These may
 CC be used as an inhibin agonist, antagonist or for eliciting an
 CC antigenic response to affect gonadal function or reproductive
 CC physiology.
 XX
 SQ Sequence 1134 BP; 182 A; 400 C; 322 G; 230 T; 0 other;
 Query Match 97.1%; Score 33; DB 7; Length 1134;
 Best Local Similarity 97.1%; Pred. No. 0.00064;
 Matches 33; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 AGGCCTCCGGAGGACCGNCTGCCCATGCCCAACT 34
 DB 758 AGGCCTCCGGAGGACCGGCTGCCCATGCCCAACT 791
 RESULT 3
 AAN70314
 ID AAN70314 standard; cDNA; 1237 BP.
 XX
 AC AAN70314;
 XX
 DT 09-APR-1991 (first entry)
 XX
 DE Sequence encoding human inhibin alpha-chain precursor.
 XX
 KW Fertility control; contraception; hormone; spermatogenesis; ss.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT CDS 3..50
 FT /*tag= a
 FT CDS 51..653
 FT /product=signal sequence
 FT /*tag= b
 FT /product=pro region
 FT mat_peptide 654..1058
 FT /*tag= c
 FT poly_A signal 1216..1221
 FT /*tag= d
 XX
 PN EP222491-A.
 XX
 PD 20-MAY-1987.
 XX
 PY 02-OCT-1986; 86EP-0307586.
 XX
 PR 12-SEP-1986; 86US-0906729.
 PR 03-OCT-1985; 85US-0783910.
 PR 10-FEB-1986; 86US-0827710.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Mason AJ, Seeburg PH;
 XX WPI: 1987-137512/20.
 DR P-PSDB; AAP70202.
 XX
 PT Recombinant human or porcine inhibin or activin - used for

PT modulating clinical condition or reproductive physiology of
 XX animals.

XX Disclosure: Fig 6A; 48pp; English.

XX A compsn. comprising human or porcine inhibin which is completely
 CC free of unidentified or porcine proteins is claimed. Also claimed
 CC are non chromosomal DNA encoding inhibin-alpha or an inhibin-beta
 CC chain. Sequencing of inhibin-encoding cDNA has led to the
 CC identification of prodomain regions located N-terminal to the
 CC mature inhibin chains that represent coordinately expressed
 CC biologically active polypeptides. The prodomain regions or
 CC prodomain immunogens are useful in monitoring preproinhibin
 CC processing in transformant cell culture or in experiments directed
 CC at modulating the clinical condtn. or reproductive physiology of
 CC animals.

XX SQ Sequence 1237 BP; 210 A; 431 C; 346 G; 250 T; 0 other;

Query Match 97.1%; Score 33; DB 8; Length 1237;

Best Local Similarity 97.1%; Pred. No. 0.00064;
 Matches 33; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 AGGCTCCGAGGAGACGCTGCCATGCCAACT 34

DB 708 AGGCTCCGAGGAGACGCTGCCATGCCAACT 741

RESULT 4

AA080040

ID AA080040 standard; DNA; 1338 BP.

XX AC AA080040;

XX DT 28-JAN-1993 (first entry)

XX Sequence encoding the 18K alpha-chain of a protein exhibiting
 DE inhibin activity and its N-terminal sequence.

XX Fertility control; inhibin; follicle stimulating hormone; inhibitor;
 KW gonadotropin; ss.

XX OS Homo sapiens.

XX FU Key Location/Qualifiers
 FT CDS 145..840

FT FT /*tag= a

FT FT /product= N-terminal sequence

FT FT 841..1245

FT FT /*tag= b

FT FT /product= 18 K chain

FT FT /note= "claimed"

XX US4737578-A.

XX DT 12-APR-1988.

XX PF 07-APR-1986; 86US-0848924.

XX XX 07-APR-1986; 86US-0848924.

XX PR 10-FEB-1986; 86US-0828435.

XX (SALK) SALK INST FOR BIOL STUD.

XX Evans RM, Rosenfeld MG, Cerelli G, Mayo KE, Spless J;

XX Rivier JEF, Vale WW;

XX WPI; 1988-119128/17.

XX P-PSDB; AAP8167.

XX New proteins with inhibin activity - esp. useful for controlling
 PT fertility in males

XX

PS Disclosure: Table 1, page 6-7; 6pp; English.

XX The inventors claim 2 proteins - A and B - each of which has a
 CC molecular weight of about 32K and is comprised of an alpha (18K) and
 CC a beta (14K) chain of human inhibin. The alpha chain is AAP80018.
 CC The beta chain is either AAP80019 or AAP80020. Proteins A and B are
 CC useful for regulating fertility of mammals. Each 32K protein
 CC exhibits inhibin activity in basal secretion of FHS but not
 CC inhibiting basal secretion of luteinizing hormone (LH).

XX SQ Sequence 1338 BP; 232 A; 433 C; 417 G; 256 T; 0 other;

Query Match 97.1%; Score 33; DB 9; Length 1338;

Best Local Similarity 97.1%; Pred. No. 0.00064;
 Matches 33; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 AGGCTCCGAGGAGACGCTGCCATGCCAACT 34

DB 895 AGGCTCCGAGGAGACGCTGCCATGCCAACT 928

RESULT 5

AAL03358/c

ID AAL03358 standard; DNA; 3422 BP.

XX AC AAL03358;

XX DT 21-NOV-2001 (first entry)

XX Human reproductive system related antigen DNA SEQ ID NO: 6046.

XX Human; reproductive system related antigen; reproductive system disorder;
 KW cancer; gene therapy; ds.

XX OS Homo sapiens.

XX PN WU200155320-A2.

XX PD 02-AUG-2001.

XX PF 17-JAN-2001; 2001WO-US01339.

XX PR 31-JAN-2000; 2000US-0179065.

XX PR 04-FEB-2000; 2000US-0180628.

XX PR 24-FEB-2000; 2000US-0184664.

XX PR 02-MAR-2000; 2000US-0186350.

XX PR 16-MAR-2000; 2000US-0189874.

XX PR 17-MAR-2000; 2000US-0190076.

XX PR 18-APR-2000; 2000US-0198123.

XX PR 19-MAY-2000; 2000US-0205515.

XX PR 07-JUN-2000; 2000US-0209467.

XX PR 28-JUN-2000; 2000US-0214886.

XX PR 30-JUN-2000; 2000US-0215135.

XX PR 07-JUL-2000; 2000US-0216647.

XX PR 07-JUL-2000; 2000US-0216880.

XX PR 11-JUL-2000; 2000US-0217487.

XX PR 11-JUL-2000; 2000US-0217496.

XX PR 14-JUL-2000; 2000US-0218290.

XX PR 26-JUL-2000; 2000US-0220963.

XX PR 26-JUL-2000; 2000US-0220964.

XX PR 14-AUG-2000; 2000US-0224518.

XX PR 14-AUG-2000; 2000US-0224519.

XX PR 14-AUG-2000; 2000US-0225213.

XX PR 14-AUG-2000; 2000US-0225214.

XX PR 14-AUG-2000; 2000US-0225266.

XX PR 14-AUG-2000; 2000US-0225267.

XX PR 14-AUG-2000; 2000US-0225268.

XX PR 14-AUG-2000; 2000US-0225270.

XX PR 14-AUG-2000; 2000US-0225447.

XX PR 14-AUG-2000; 2000US-0225757.

XX PR 14-AUG-2000; 2000US-0225758.

XX PR 14-AUG-2000; 2000US-0225759.

XX PR 18-AUG-2000; 2000US-0226279.

PR 22-AUG-2000; 2000US-0226691.
PR 22-AUG-2000; 2000US-0226668.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0239950.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0244674.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.

PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 01-DEC-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 05-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
XX WPI; 2001-465570/50.
XX
PT Isolated nucleic acid molecule encoding a reproductive system antigen -
is used in preventing, treating or ameliorating a medical condition -
XX
PS Disclosure; SEQ ID NO 6046; 1297pp + Sequence Listing; English.
XX
CC The present invention provides the protein and coding sequences of a
number of human reproductive system related antigens. These can be used
in the prevention and treatment of reproductive system disorders.
CC including cancer. The present sequence is a genomic sequence encoding a
protein of the invention.
XX
SQ Sequence 3422 BP; 806 A; 898 C; 962 G; 756 T; 0 other;

Query Match 97.18; Score 33; DH 22; Length 3422;
Best Local Similarity 97.18; Pred. No. 0.00069;
Matches 33; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 AGGCTCCGGAGGACCGNCTGCCATGCCCAACT 34
|||||
Db 538 AGGCTCCGGAGGACCGGCTGCCATGCCCAACT 505

RESULT 6
AAL03360/c
ID AAL03360 standard; DNA: 3422 BP.
XX
AC AAL03360;
XX
DT 21-NOV-2001 (first entry)
XX
DE Human reproductive system related antigen DNA SEQ ID NO: 6048.
XX
KW Human; reproductive system related antigen; reproductive system disorder;
cancer; gene therapy; ds.


```
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-465570/50.
XX
PT Isolated nucleic acid molecule encoding a reproductive system antigen -
PT is used in preventing, treating or ameliorating a medical condition -
XX
PS Disclosure; SEQ ID NO 6048; 1297pp + Sequence Listing; English.
XX
CC The present invention provides the protein and coding sequences of a
CC number of human reproductive system related antigens. These can be used
CC in the prevention and treatment of reproductive system disorders,
CC including cancer. The present sequence is a genomic sequence encoding a
CC protein of the invention.
XX
SQ Sequence 3422 BP; 806 A; 858 C; 962 G; 756 T; 0 other;

Query Match 97.1%; Score 33; DB 22; Length 3422;
Best Local Similarity 97.1%; Pred. No. 0.00069;
Matches 33; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 AGGCTCCGAGGACCGNCTGCCATGCCCAACT 34
   |||||||
DB 538 AGGCTCCGAGGACCGNCTGCCATGCCCAACT 505

RESULT 7
AAS28909/c
ID AAS28909 standard; DNA; 3422 BP.
XX
AC AAS28909;
XX
XX
DT 07-NOV-2001 (first entry)
XX
DE Human immunoglobulin encoding genomic DNA SEQ ID No 271.
XX
KW Immunoglobulin; signal transduction pathway protein; cancer; ds;
KW antisense therapy; gene therapy; neurological disorder; renal disorder;
KW cardiovascular disorder; gastrointestinal disorder; pulmonary disorder;
KW reproductive disorder; immune system disorder; proliferative disorder;
KW muscular disorder.
XX
OS Homo sapiens.
XX
XX
PN WO200155315-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01326.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214880.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226688.
PR 23-AUG-2000; 2000US-0227182.
PR 30-AUG-2000; 2000US-0227009.
PR 01-SEP-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 06-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
```

PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251866.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 11-DEC-2000; 2000US-0251990.
PR 05-JAN-2001; 2001US-0254097.
PR 05-JAN-2001; 2001US-0254097.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
XX Rosen CA, Barash SC, Ruben SM;
XX
XX WPI; 2001-457725/49.
XX
PT Isolated novel immunoglobulin polypeptide for monitoring the presence
PT and progression of diseases and for diagnosis -
XX
PS Claim 1; SEQ ID No 271; 551pp; English.
XX

CC Sequences AAS2887B-AAS28926 represent genomic DNA molecules which encode
CC the immunoglobulin polypeptides of the invention. The polynucleotides and
CC polypeptides can be used to diagnose a pathological condition or a
CC susceptibility to a pathological condition in a subject by determining
CC the presence or absence of a mutation in a DNA sequence or determining
CC the presence or amount of expression of the protein. Alternatively the
CC identification of a binding partner to a sequence allows determination of
CC changes in protein activity. The sequences can be used as research tools
CC for receptors or other signal transduction pathway proteins that interact
CC with the polypeptides of the invention and can be used to treat, prevent
CC or diagnose various types of disorders such as neurological disorders,
CC cardiovascular disorders, gastrointestinal disorders, reproductive
CC disorders, immune system disorders, renal disorders, muscular disorders,
CC pulmonary disorders, proliferative disorders and cancer.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pat_sequences.
XX
SQ Sequence 3422 BP; 806 A; 698 C; 962 G; 756 T; 0 other;

Query Match 97.1%; Score 33; DB 22; Length 3422;
Best Local Similarity 97.1%; Pred. No. 0.00069;
Matches 33; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 AGGCTCCGGAGGACCGCTGCCCATGCCAACT 34
|||||
DB 538 AGGCTCCGGAGGACCGCTGCCCATGCCAACT 505

RESULT 8

AAS28911
ID AAS28911 standard; DNA; 3422 BP.
XX
AC AAS28911;
XX
DT 07-NOV-2001 (first entry)
XX
DE Human immunoglobulin encoding genomic DNA SEQ ID No 273.
XX
KW Immunoglobulin; signal transduction pathway protein; cancer; ds;
KW antisense therapy; gene therapy; neurological disorder; renal disorder;
KW cardiovascular disorder; gastrointestinal disorder; pulmonary disorder;
KW reproductive disorder; immune system disorder; proliferative disorder;
KW muscular disorder.
XX
OS Homo sapiens.
XX
XX WO2001:55315-A2.
XX
XX 02-AUG-2001.
XX
XX 17-JAN-2001; 2001WO-US01326.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0218880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220964.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226688.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.


```

DE Sequence encoding bovine inhibin A subunit.
KW Hormone; inhibin agonist; antagonist; reproductive; gonad; ss.
XX
XX Bos taurus.
XX
XX Key Location/Qualifiers
XX CDS 61..240
XX
XX mat_peptide /*tag= a
XX 241..1143
XX /*tag= b
XX
XX W08606076-A.
XX
XX 23-OCT-1986.
XX
XX 14-APR-1986; 86W0-AU00097.
XX
XX 20-DEC-1985; 85AU-0003961.
XX 18-APR-1985; 85AU-0000194.
XX 06-SEP-1985; 85AU-0002320.
XX 29-OCT-1985; 85AU-0003157.
XX 19-DEC-1985; 85AU-0003960.
XX 01-JAN-1986; 86AU-0059039.
XX 02-APR-1987; 87AU-0071015.
XX 05-MAY-1986; 86CN-0103459.
XX
XX (BIOT-) BIOTECHN AUSTR PTY.
XX (MONU) MONASH UNIV.
XX (HENR-) PRICE HENRY'S HOSPITAL.
XX (SVIN-) ST VINCENTS'S INST MED RE.
XX
XX Forage R, Stewart A, Robertson D, Dekretser DM;
XX
XX WPI; 1986-291647/44.
XX P-PSDB; AAF60517.
XX
XX New polynucleotide sequences and recombinant DNA - encoding
XX inhibin and synthetic peptides useful for affecting gonadal
XX function
XX
XX Claim 8; Fig 5; 71pp; English.
XX
XX DNA encoding inhibin and inhibin or part, analogues, homologues or
XX precursors thereof when produced by recombinant techniques are also
XX claimed, as well as pharmaceutical compositions thereof. These may
XX be used as an inhibin agonist, antagonist or for eliciting an
XX antigenic response to affect gonadal function or reproductive
XX physiology.
XX
XX Sequence 1182 BP; 173 A; 414 C; 363 G; 232 T; 0 other;
XX
Query Match 73.5%; Score 25; DB 7; Length 1182;
Best Local Similarity 82.4%; Pred. No. 1;
Matches 28; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 1 AGGCCTCCGAGGAGAACGNCCTGCGCATGCCAACT 34
||||| ||||| || ||||| |||||
Db 793 AGGCCTCCAGAGGAGCGCGCGCCATGCCGACT 826

RESULT 10
AAN70310
1D AAN70310 standard; cDNA; 1343 BP.
XX
XX AAN70310;
XX
XX 09-APR-1991 (first entry)
XX
XX Sequence encoding porcine inhibin alpha-chain precursor.
XX
XX Fertility control; contraception; hormone; spermatogenesis; ss.
XX

```

```

OS Sus scrofa domestica.
XX
XX Key Location/Qualifiers
XX CDS 72..761
XX /*tag= a
XX
XX mat_peptide /product=hydrophobic signal sequence a pro-region
XX 762..1166
XX /*tag= b
XX
XX polyA_signal 1300..1305
XX /*tag= c
XX
XX EP222491-A.
XX
XX 20-MAY-1987.
XX
XX 02-OCT-1986; 86EP-0307586.
XX
XX 12-SEP-1986; 86US-0906729.
XX 03-OCT-1985; 85US-0783910.
XX 10-FEB-1986; 86US-0827710.
XX
XX (GETH ) GENENTECH INC.
XX
XX Mason AJ, Seeburg PH;
XX
XX WPI; 1987-137512/20.
XX P-PSDB; AAF70199.
XX
XX Recombinant human or porcine inhibin or activin - used for
XX modulating clinical condition or reproductive physiology of
XX animals.
XX
XX Disclosure; Fig 1B; 48pp; English.
XX
XX A compsn. comprising human or porcine inhibin which is completely
XX free of unidentified or porcine proteins is claimed. Also claimed
XX are non chromosomal DNA encoding inhibin-alpha or an inhibin-beta
XX chain. Sequencing of inhibin-encoding cDNA has led to the
XX identification of prodomain regions located N-terminal to the
XX mature inhibin chains that represent coordinately expressed
XX biologically active polypeptides. The prodomain regions or
XX prodomain immunogens are useful in monitoring preinhibin
XX processing in transformant cell culture or in experiments directed
XX at modulating the clinical condn. or reproductive physiology of
XX animals.
XX
XX Sequence 1343 BP; 196 A; 472 C; 417 258 T; 0 other;
XX
Query Match 68.8%; Score 23.1; DB 8; Length 1343;
Best Local Similarity 79.4%; Pred. No. 4.6;
Matches 27; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 1 AGGCCTCCGAGGAGAACGNCCTGCGCATGCCAACT 34
||||| ||||| ||||| ||||| |||||
Db 816 AGCCCCCGAGGAGAACCGCTGCTGCACGCCGACT 849

RESULT 11
AAD06014
1D AAD06014 standard; DNA; 5145 BP.
XX
XX AAD06014;
XX
XX 31-JUL-2001 (first entry)
XX
XX Human neuronal apoptosis regulated candidate (NARC) 25 DNA.
XX
XX Human; neuronal apoptosis regulated candidate 25; NARC 25; cytostatic;
XX chromosome mapping; gene therapy; antisense therapy; lung disorder;
XX central nervous system disorder; apoptosis; spleen disorder; angina;
XX tuberculosis; Goodpasture's syndrome; liver disorder; jaundice;
XX infectious disorder; brain disorder; cerebral oedema; gonorrhoea;
XX heart disorder; kidney disorder; glomerulonephritis; testes; virucide;

```

XX	Drosophila; developmental biology; cell signalling; insecticide;
KW	pharmaceutical; gene; ss.
XX	Drosophila melanogaster.
PN	WO200171042-A2.
XX	27-SEP-2001.
PD	XX
XX	23-MAR-2001; 2001WO-US09231.
XX	XX
PF	23-MAR-2000; 2000US-191637P.
PR	11-JUL-2000; 2000US-0614150.
XX	(PEKE) PE CORP NY.
PA	Venter JC, Adams M, Li PWJ, Myers EW:
XX	WPI: 2001-556860/75.
PI	P-PSDB; ABB68554.
DR	XX
DR	New isolated nucleic acid detection reagent for detecting 1000 or more
XX	genes from Drosophila and for elucidating cell signalling and cell-cell
PT	interactions -
PT	Claim 1; SEQ ID NO 32453; Zipp + Sequence Listing; English.
PS	XX
CC	The invention relates to an isolated nucleic acid detection reagent
CC	capable of detecting 1000 or more genes from Drosophila. The invention is
CC	useful in developmental biology and in elucidating cell signalling and
CC	cell-cell interactions in higher eukaryotes for the development of
CC	insecticides, therapeutics and pharmaceutical drugs. The invention
CC	discloses genomic DNA sequences (ABL16176-ABL30511); expressed DNA
CC	sequences (ABL01840-ABL16175) and the encoded proteins
CC	(ABB57737-ABB57072).
CC	The sequence data for this patent did not form part of the printed
CC	specification, but was obtained in electronic format directly from WIPO
CC	at ftp.wipo.int/pub/published_pat_sequences.
XX	XX
SQ	Sequence 5172 BP; 1286 A; 1567 C; 1489 G; 830 T; 0 other;
Query Match	58.2%; Score 19.8; DB 23; Length 5172;
Best Local Similarity	75.0%; Pred. No. 1.4e+02;
Matches 24; Conservative	0; Mismatches 8; Indels 0; Gaps 0;
QY	1 AGGCTCGGAGGACGCNCTGCCATCCCAA 32
Db	2977 ASGCGGGGGUGAAGCCTCGCGTCCCA 3008
RESULT l3	
ABL12656/r:	
ID	ABL12656 standard; cDNA; 6410 BP.
XX	XX
AC	ABL12656;
XX	XX
DT	26-MAR-2002 (first entry)
XX	XX
DE	Drosophila melanogaster expressed polynucleotide SEQ ID NO 32450.
XX	XX
KW	Drosophila; developmental biology; cell signalling; insecticide;
KW	pharmaceutical; gene; ss.
XX	Drosophila melanogaster.
OS	WO200171042-A2.
XX	27-SEP-2001.
XX	XX
PF	23-MAR-2001; 2001WO-US09231.
XX	XX
PR	23-MAR-2000; 2000US-191637P.

```

PR 11-JUL-2000; 2000US-0614150.
PA (PEKE ) PE CORP NY.
XX
PI Venter JC, Adams M, Li PWD, Myers EW;
XX
XX WPI: 2001-656860/75.
XX P-PSDB; ABB68553.
XX
PT New isolated nucleic acid detection reagent for detecting 1000 or more
PT genes from Drosophila and for elucidating cell signalling and cell-cell
PT interactions -
XX
XX Claim 1; SEQ ID NO 32450; 21pp + Sequence Listing; English.
XX
XX The invention relates to an isolated nucleic acid detection reagent
XX capable of detecting 1000 or more genes from Drosophila. The invention is
XX useful in developmental biology and in elucidating cell signalling and
XX cell-cell interactions in higher eukaryotes for the development of
XX insecticides, therapeutics and pharmaceutical drugs. The invention
XX discloses genomic DNA sequences (AB116176-AB130511), expressed DNA
XX sequences (AB101840-AB16175) and the encoded proteins
XX (AB157737-AB172072).
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequences.
XX
XX Sequence 6410 BP; 1179 A; 1787 C; 1832 G; 1612 T; 0 other;
SQ
Query Match 58.2%; Score 19.8; DB 23; Length 6410;
Best Local Similarity 75.0%; Pred. No. 1.5e+02;
Matches 24; Conservative 0; Mismatches 8; Indels 0; Gaps 0;
QY 1 AGCGCTCGGAGAACGCTGCCATGCCAA 32
DB 111111111111111111111111
DB 3335 AAGCGCGCGTGGAAACCGCTGCCCGCCAA 3304
RESULT 14
AAT06947
ID AAT06947 standard; cDNA; 1500 BP.
XX
AC AAT06947;
XX
XX 26-JUN-1996 (first entry)
XX
XX C-promoter binding factor 1 coding sequence.
XX
XX C-promoter binding factor 1; CBFl; transcription factor; TF; EBNA2;
XX Epstein-Barr virus; CBFl-TF transcription complex; viral infection;
XX bacterial infection; fungal infection; metabolic disease; inflammation;
XX genetic disease; cell growth dysfunction; regulatory dysfunction;
XX neoplasm; hypersensitivity; human; animal; plant; therapy; ds.
XX
XX Synthetic.
XX
XX WO9532307-A1.
XX
XX 30-NOV-1995.
XX
XX 17-MAY-1995; 95WO-US05966.
XX
XX 20-MAY-1994; 94US-0246977.
XX
XX (TULA-) TULARIK INC.
XX
XX Henkel T, Peterson MG;
XX
XX WPI: 1996-020599/02.
XX P-PSDB; AAR86790.
XX
XX Screening cpds, which disrupt complex formation between C-promoter
XX binding factor and transcription factor - potentially useful for
PT

```

```

PT treating diseases involving the expression of a gene modulated by
PT such complex formation
XX
XX Claim 1; Page 22-24; 34pp; English.
XX
XX This sequence represents the cDNA encoding C-promoter binding factor-1
XX (CBFl). A partially purified form of the protein encoded by this sequence
XX is used in the method of the invention. The method is used for screening
XX a chemical library for pharmacological agents. The protein is able to
XX selectively bind to a transcription factor (TF) (such as Epstein-Barr
XX virus EBNA2), and a test compound. The sample is incubated under
XX conditions that allow the protein and the TF to bind. The presence or
XX absence of binding of CBFl and TF is then detected. Absence of binding
XX indicates that the test compound disrupts CBFl-TF dependent gene
XX expression. This method is also modified to include a labelled nucleic
XX acid sequence containing the sequence G3GA in the incubation mixture.
XX When the nucleic acid is used, the presence or absence of the binding of
XX the CBFl-TF transcription complex to the nucleic acid sequence is
XX detected. The test compounds identified are potentially useful for
XX treating diseases associated with expression of a gene modulated by a
XX CBFl-TF transcription complex. These include viral, bacterial or fungal
XX infections, metabolic or genetic diseases and cell growth/regulatory
XX dysfunction (such as neoplasms, inflammation or hypersensitivity), in
XX humans animals or plants.
XX
XX Sequence 1500 BP; 465 A; 319 C; 346 G; 370 T; 0 other;
SQ
Query Match 57.6%; Score 19.6; DB 17; Length 1500;
Best Local Similarity 81.5%; Pred. No. 1.6e+02;
Matches 22; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
QY 3 GCCTCCGAGGAAACGCTGCCATGC 29
DB 111111111111111111111111
DB 21 GCCCGCGGAGGAGCGCGCTGCCATGC 47
RESULT 15
AAX39671
ID AAX39671 standard; DNA; 1580 BP.
XX
AC AAX39671;
XX
XX 02-JUL-1999 (first entry)
XX
XX Renal cancer associated gene.
XX
XX Cancer associated antigen; diagnosis; research; treatment; human;
XX breast cancer; colon cancer; gastric cancer; renal cancer; lung cancer;
XX prostate cancer; ss.
XX
XX Homo sapiens.
XX
XX WO9904265-A2.
XX
XX 28-JAN-1999.
XX
XX 15-JUL-1998; 98WO-US14679.
XX
XX 22-JUN-1998; 98US-0102322.
XX 17-JUL-1997; 97US-0896164.
XX 10-OCT-1997; 97US-0061599.
XX 10-OCT-1997; 97US-0061765.
XX 10-OCT-1997; 97US-0948705.
XX 11-OCT-1997; 97GB-0021697.
XX
XX (LUDW-) LUDWIG INST CANCER RES.
XX
XX Chen Y, Gout I, Gure A, O'Hare M, Obata Y, Old LJ;
XX Pfreundschuh M, Sahin U, Scanlan MJ, Stockert E;
XX Tureci O;
XX
XX WPI: 1999-132448/11.
XX
XX
XX
XX

```

PT New isolated cancer associated nucleic acids and polypeptides -
PT isolated using sera from cancer patients, used to develop products
PT for the diagnosis, monitoring or treatment of cancers
XX
XX
PS Claim 67; Page 481-482; 787pp; English.
XX
CC The invention relates to a method for diagnosing a disorder characterised
CC by expression of a human cancer associated antigen precursor coded for by
CC a nucleic acid molecule (NAM). The method comprises: (a) contacting a
CC biological sample isolated from a subject with an agent that specifically
CC binds to the NAM, an expression product or a fragment of an expression
CC product complexed with an HLA molecule; and (b) determining the
CC interaction between the agent and the NAM or the expression product as a
CC determination of the disorder. The products and methods can be used in
CC the diagnosis, monitoring, research, or treatment of conditions
CC characterised by the expression of various cancer associated antigens.
CC The invention provides nucleic acid sequences and encoded polypeptides
CC which are cancer associated antigen precursors expressed in human breast
CC cancer, renal cancer, colon cancer, gastric cancer, prostate cancer and
CC lung cancer.
XX
SQ Sequence 1580 BP; 481 A; 352 C; 359 G; 388 T; 0 other;

Query Match 57.6%; Score 19.6; DB 20; Length 1580;
Best Local Similarity 81.5%; Pred. No. 1.6e-02;
Matches 22; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 3 GCCTCCGGAGGAGCGGCTGCGCATGC 29
||| ||||| || ||||| |||||
Db 99 GCGCGGAGGAGCGGCTGCGCATGC 125

Search completed: March 11, 2003, 00:17:20
Job time : 158.822 secs